Carcinoembryonic antigen (CEA) is a protein usually produced in the developing fetus and disappears or is absent in adults. Abnormal amounts of this protein may lead to cancer. CEA test is performed to measure the level of proteins and check for the recurrence of colon and other cancers in patients already diagnosed with cancer. The normal accepted range of this protein is 0 micrograms to 0.25 micrograms per liter. Elevated levels of CEA in the patients recently treated for cancer, indicates recurrence of the cancer.
These elevated levels are attributed to different types of cancers and other conditions such as cholecystitis, lung infection, heavy smoking, inflammatory bowel diseases, peptic ulcer, etc. High levels of CEA are also found in the patients who are not diagnosed with cancer which might increase the risk of acquiring cancer. Hematoma (blood accumulating under the skin), infection, dizziness and excessive bleeding are some of the risks associated with abnormal levels of CEA. The abnormal levels of CEA in the body can be detected by using arcitumomab a monoclonal antibody; these are commonly used in the identification of glycoprotein expression in tissue samples.
The continuous technological advances followed by discovery of specific antigens, biomarkers, and etc. form the prime reason for tremendous growth of CEA testing market. The market can be segmented by instrumentation and on the basis of number of tests performed in specific geographies elucidating the market by volume and geography. Qualitative analysis of the regulatory policies and patent protection can highlight the need of CEA testing market.
The major factors influencing the growth of the market are rise in geriatric population, technological breakthroughs that aids in revealing the genetic basis of the disease, increased accuracy of the diagnostic procedures and rigorous research and development initiatives. Lack of awareness and availability of novel technological solutions might pose a challenge to the growth of CEA testing market. The companies competing in this market are Abbott Laboratories, Siemens Healthcare, bioMerieux, Danaher Corporation (Beckman Coulter), Myriad Genetics, Epigenomics, Qiagen N.V., and Life Technologies Corporation.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Browse Upcoming Reports @:http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html
Transparency Market Research (TMR) is a market intelligence company providing global business research reports and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers.
TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources along with various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information which is indispensable for businesses to sustain their competitive edge.
90 State Street,
Albany NY - 12207